CIK 0000921299
- Non-accelerated filer
- Smaller reporting company
KYNTRA BIO, INC.
Sign in to watch- Ticker
- KYNB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770357827
- Phone
- +1 415-978-1200
- Business address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
- Former names
- FIBROGEN INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-10-07 | Kurkijarvi Kalevi Director | Exercise or conversion · Stock Option (Right to Buy) | −6,000 | 6,000 | ||
| 2019-09-20 | Chung Christine SVP, China Operations | Exercise or conversion | +5,625 | $19.39 | $109K | 145,253 |
| 2019-09-20 | Chung Christine SVP, China Operations | Sale | −5,625 | $39.87 | $224K | 139,628 |
| 2019-09-20 | Chung Christine SVP, China Operations | Exercise or conversion · Stock Option (Right to Buy) | −5,625 | 45,209 | ||
| 2019-09-19 | Chung Christine SVP, China Operations | Exercise or conversion | +2,120 | $19.39 | $41K | 145,253 |
| 2019-09-19 | Chung Christine SVP, China Operations | Sale | −2,225 | $40.00 | $89K | 143,028 |
| 2019-09-19 | Chung Christine SVP, China Operations | Sale | −3,400 | $40.75 | $139K | 139,628 |
| 2019-09-19 | Chung Christine SVP, China Operations | Exercise or conversion · Stock Option (Right to Buy) | −2,120 | 50,834 | ||
| 2019-09-18 | Schoeneck James A Interim CEO | Grant or award | +57,300 | 62,000 | ||
| 2019-09-18 | Schoeneck James A Interim CEO | Grant or award · Stock Option (Right to Buy) | +97,100 | 97,100 | ||
| 2019-09-17 | Cotroneo Pat SVP, Finance and CFO | Sale | −3,201 | $41.38 | $132K | 244,432 |
| 2019-09-16 | Yu K Peony Chief Medical Officer | Sale | −3,419 | $40.92 | $140K | 175,240 |
| 2019-09-09 | Kurkijarvi Kalevi Director | Exercise or conversion | +6,000 | $5.95 | $36K | 34,400 |
| 2019-09-09 | Kurkijarvi Kalevi Director | Sale | −5,580 | $40.90 | $228K | 28,820 |
| 2019-09-09 | Kurkijarvi Kalevi Director | Sale | −420 | $41.67 | $18K | 28,400 |
| 2019-09-09 | Kurkijarvi Kalevi Director | Exercise or conversion · Stock Option (Right to Buy) | −6,000 | 0 | ||
| 2019-09-06 | Yu K Peony Chief Medical Officer | Shares withheld for taxes | −8,317 | $41.68 | $347K | 178,659 |
| 2019-09-06 | Kouchakji Elias SVP, Clinical Dev, Drug Safety | Shares withheld for taxes | −5,541 | $41.68 | $231K | 103,658 |
| 2019-09-06 | Cotroneo Pat SVP, Finance and CFO | Shares withheld for taxes | −3,144 | $41.68 | $131K | 247,633 |
| 2019-09-06 | Chung Christine SVP, China Operations | Shares withheld for taxes | −8,437 | $41.68 | $352K | 143,133 |
Page 27 of 33 · 651 trades